Real-world use of Octave Bioscience’s artificial intelligence (AI)-powered blood test for classifying multiple sclerosis (MS) activity has increased substantially in the few years since its commercial U.S. launch. In clinical practice, the multiple sclerosis disease activity (MSDA) test has mainly been used for routine monitoring, with additional uses including baseline assessment, risk stratification at diagnosis, […]
The post AAN 2026: AI-powered MS blood test sees growing use in real-world care appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com